Brief: Cero Therapeutics Announces Critical Patent Application Allowances From The U.S. Patent Office
10/04/2025 15:18
April 10 (Reuters) - CERo Therapeutics Holdings Inc CERO.O: CERO THERAPEUTICS HOLDINGS, INC. ANNOUNCES CRITICAL PATENT APPLICATION ALLOWANCES FROM THE U.S. PATENT OFFICE COVERING COMPANY’S LEAD COMPOUND CER-1236 Source text: ID:nGNE64NCNq Further company coverage: CERO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on CERo Therapeutics Holdings
See all newsBrief: Cero Therapeutics Hearing Review Council Issued Decision
Brief: Cero Therapeutics Provides Clinical Update On Phase 1 Trial Of Cer-1236 In Aml (Certaint-1)
Brief: Cero Therapeutics Provides Clinical Update On Phase 1 Trial Of Cer-1236 In Aml
Brief: Cero Therapeutics Provides Clinical Update On Phase 1 Clinical Trial
Brief: Cero Therapeutics Holdings Inc - Continues To Evaluate Additional Options For Up-List